MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
Board) of MEDITE Cancer Diagnostics, Inc. (the Company) held a
meeting whereby it unanimously voted to appoint Susan Weisman to
the position of Chief Financial Officer of the Company to serve
until such time as his removal or resignation. to Ms. Weismans
Executive Employment Agreement with the Company, the Commencement
Date of her appointment shall be April 26, 2017. She shall
receive an annual base salary of $120,000. She shall also be
granted 200,000 restricted shares of the Companys common stock
(the Shares). The Shares will vest in three (3) equal
installments on each of the first three annual anniversary dates
of Ms. Weismans appointment, so long as she remains employed by
the Company through each such vesting date. Ms. Weisman shall
also be entitled to annual performance bonuses, benefits and
vacation in accordance with the Companys current policy.
progressive experience in consulting, executive positions with
both public and private companies and various industries,
including financial services, technology, real estate, medical
services and manufacturing. She has an extensive history of
increasing responsibility, achievement of growth in all positions
across product/service/technology. From August 2008 until the
present, Ms. Weisman operated Finance and Strategic Consultants,
LLC, where she provided advisory services to the Company as well
as a healthcare service provider and a healthcare technology,
various other technology companies, financial services companies
as well as real estate and various other industries. From
September 20008 to October 2010 Ms. Weisman worked for AFC, LLC.,
an investment company of Mitsui Co (USA) as Chief Financial
Officer, Acting Chief Executive Officer and Chief Liquidation
Officer a sub-prime auto finance company reporting to Mitsui Co
(USA). From September 2007 to August 2008, Ms. Weisman was the
Chief Financial Officer and Chief Operating Officer for CU
Business Capital, LLC. From 2004 to 2007, a credit union service
organization. Ms. Weisman was Chief Financial Officer and
Director of Coach Industries Group, a company required to file
reports with the Securities and Exchange Commission, a financial
services company offering lease finance, insurance, independent
contractor settlement to commercial fleet operators, as well as
the manufacturer of modified commercial vehicles. From 1990 to
2000, Ms. Weisman was Controller and acting CFO of a $4.2 Billion
savings bank holding company, BankAtlantic Bancorp, a company
required to file reports with the Securities and Exchange
Commission which included BankAtlantic, a federal savings bank,
BankAtlantic Development Corporation, a real estate development
company, Ryan, Beck Co. an investment banking company and various
internet start-up investments. From 1986 to 1990 Ms. Weisman
worked for KPMG, LLC, a global accounting firm. Ms. Weisman
obtained a B.S. Degree in Economics from City University of New
York – Brooklyn College. Ms. Weisman is a certified public
accountant New York (inactive status). Except as set forth above,
Ms. Weisman has not served as an officer and director of a
company required to file reports with the Securities and Exchange
Commission.
Exhibit No.
|
Description
|
|
10.1
|
Executive Employment Agreement
|
|
99.1
|
Press Release
|
About MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT)
MEDITE Cancer Diagnostics, Inc. (MEDITE), formerly CytoCore, Inc., is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases. The Company develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. The Company offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. The Company offers USE33, an ultrasonic decalcification instrument that runs the process under controlled temperatures. The Company also offers TPC15 Duo or Trio, TES99, TES Valida, M530, A550, M380, TST44 and COT20 linear staining systems. In addition, the Company also offers RCM9000, ACS720 and TWISTER glass and robotic coverslippers. MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT) Recent Trading Information
MEDITE CANCER DIAGNOSTICS, INC. (OTCMKTS:MDIT) closed its last trading session 00.000 at 0.809 with shares trading hands.